Chemotherapy News and Research

Latest Chemotherapy News and Research

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma, the most common type of liver cancer.

16 Dec 2013

Switching chemotherapy does not improve survival in metastatic breast cancer patients with CTCs

For women with metastatic breast cancer who had elevated amounts of circulating tumor cells (CTCs) in their blood after a first line of chemotherapy, switching immediately to a different chemotherapy did not improve overall survival or time to progression, according to the results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

16 Dec 2013

New technologies unveiled to provide expert care and streamline the process of treating breast cancer

Breast cancer patients are moms, wives, and caretakers. They are teachers, nurses, physicians and heads of industry. Today, more than ever before, women are delicately balancing the various roles of their lives. A breast cancer diagnosis and the treatment that follows is yet another challenge that unfortunately many women need to accommodate in their already busy schedules. That's why Jersey Shore University Medical Center, Ocean Medical Center and Riverview Medical Center offer technologies that provide expert care and streamline the process of treating breast cancer.

14 Dec 2013

Analysis provides first empirical evidence on how shared savings ACO model affect quality of care

Approximately 10 percent of Medicare spending is for cancer care, and Medicare spending is nearly four times higher for beneficiaries with cancer than in those without the disease. Little is known about how to curb spending growth while maintaining or improving quality of care for these high-risk, high-cost patients.

14 Dec 2013

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

Arthur L. Day, M.D., professor of neurosurgery at The University of Texas Health Science Center at Houston and a neurosurgeon at the Mischer Neuroscience Institute at Memorial Hermann-Texas Medical Center, has received one of the top honors awarded by the Congress of Neurological Surgeons.

14 Dec 2013

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

14 Dec 2013

Researchers test promising new breast cancer drugs

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

14 Dec 2013

UTHealth Medical School professor recognized for excellence in sarcoma treatment

Rex Marco, M.D., professor in the Department of Orthopaedic Surgery at The University of Texas Health Science Center at Houston Medical School, is the recipient of an award recognizing excellence in the treatment of a type of cancer called sarcoma.

14 Dec 2013

Cetuximab fails in second-line combination for recurrent NSCLC

Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy.

13 Dec 2013

Deep genome sequencing used to predict clinical outcomes in patients with breast cancer tumors

New research from University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University examined how changes in the genetic composition of breast cancer tumors after brief exposure to either biologic therapy or chemotherapy can predict future clinical outcomes in patients.

13 Dec 2013

ESMO’s position paper highlights role of oncologists toward quality cancer care

Medical oncologists have a vital role to play in cancer care, particularly as treatments become ever more complex, a new position statement from the European Society for Medical Oncology says.

13 Dec 2013

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.

13 Dec 2013

AVEO announces data from planned interim analysis of Phase 2 BATON study in CRC patients

AVEO Oncology today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.

13 Dec 2013

Genomic tests help in selecting the most effective therapy for breast cancer

Genomic tests that determine the molecular subtype of a woman's breast cancer provide a more precise prognosis and valuable guidance about the best treatment, according to new research led by Massimo Cristofanilli, M.D, Director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals.

13 Dec 2013

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

13 Dec 2013

Novel ISM strategy enables selection of potentially effective cancer therapies for patients

A new individualized systems medicine strategy, developed at the Institute for Molecular Medicine Finland FIMM and the Helsinki University Central Hospital, enables a selection of potentially effective cancer therapies for individual patients. The promising results achieved by applying this strategy to chemoresistant adult acute myeloid leukemia patients have been recently published in the Cancer Discovery journal.

13 Dec 2013

Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

13 Dec 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Switching chemotherapy does not improve survival in metastatic breast cancer patients with CTCs

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Study could lead towards a personalised medicine for chemoresistant lymphomata

New technologies unveiled to provide expert care and streamline the process of treating breast cancer

Analysis provides first empirical evidence on how shared savings ACO model affect quality of care

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Researchers test promising new breast cancer drugs

UTHealth Medical School professor recognized for excellence in sarcoma treatment

Cetuximab fails in second-line combination for recurrent NSCLC

Deep genome sequencing used to predict clinical outcomes in patients with breast cancer tumors

ESMO’s position paper highlights role of oncologists toward quality cancer care

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

AVEO announces data from planned interim analysis of Phase 2 BATON study in CRC patients

Genomic tests help in selecting the most effective therapy for breast cancer

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Novel ISM strategy enables selection of potentially effective cancer therapies for patients

Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in